HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Clinical trials evaluating vorinostat and other HDAC inhibitors have shown their ability to induce objective responses, including complete or partial remissions, and improve symptoms in CTCL patients who have failed other treatments.